Literature DB >> 32697940

Neutralizing the Neutralizers in AAV Gene Therapy.

Roland W Herzog1, Moanaro Biswas2.   

Abstract

Mesh:

Substances:

Year:  2020        PMID: 32697940      PMCID: PMC7403453          DOI: 10.1016/j.ymthe.2020.07.015

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


× No keyword cloud information.
  3 in total

1.  IgG-cleaving endopeptidase enables in vivo gene therapy in the presence of anti-AAV neutralizing antibodies.

Authors:  Christian Leborgne; Elena Barbon; Jeffrey M Alexander; Hayley Hanby; Sandrine Delignat; Daniel M Cohen; Fanny Collaud; Saghana Muraleetharan; Dan Lupo; Joseph Silverberg; Karen Huang; Laetitia van Wittengerghe; Béatrice Marolleau; Adeline Miranda; Anna Fabiano; Victoria Daventure; Heena Beck; Xavier M Anguela; Giuseppe Ronzitti; Sean M Armour; Sebastien Lacroix-Desmazes; Federico Mingozzi
Journal:  Nat Med       Date:  2020-06-01       Impact factor: 53.440

Review 2.  AAV Vector Immunogenicity in Humans: A Long Journey to Successful Gene Transfer.

Authors:  Helena Costa Verdera; Klaudia Kuranda; Federico Mingozzi
Journal:  Mol Ther       Date:  2020-01-10       Impact factor: 11.454

3.  ASGCT Meeting Showcases Fast-Paced Development of Gene and Cell Therapy Technologies.

Authors:  Roland W Herzog; Robert M Frederickson
Journal:  Mol Ther       Date:  2020-06-19       Impact factor: 11.454

  3 in total
  2 in total

Review 1.  CRISPR Modeling and Correction of Cardiovascular Disease.

Authors:  Ning Liu; Eric N Olson
Journal:  Circ Res       Date:  2022-06-09       Impact factor: 23.213

Review 2.  Adeno-Associated Viruses (AAV) and Host Immunity - A Race Between the Hare and the Hedgehog.

Authors:  Kleopatra Rapti; Dirk Grimm
Journal:  Front Immunol       Date:  2021-10-29       Impact factor: 7.561

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.